Skip to main content
Premium Trial:

Request an Annual Quote

Silicon Biosystems, Swift Ink Deal to Join NGS, Tumor Cell Isolation Technologies

NEW YORK (GenomeWeb) – Silicon Biosystems Menarini and Swift Biosciences announced today that they have formed a partnership to join their respective technologies to create a system for next-generation sequencing of tumor cells obtained from formalin-fixed, paraffin-embedded (FFPE) samples.

Under the deal, Silicon Biosystems will develop new workflows that combine its DEPArray single-cell isolation platform with Swift's Accel-NGS DNA library kits and Accel-Amplicon panels. Additional terms were not disclosed.

"Offering our DEPArray system owners the simple and optimized sequencing solution that Swift Biosciences provides will guarantee them reliable and high-quality results that translational research requires," Silicon Biosystems CEO Giuseppe Giorgini said in a statement.

"There is a treasure trove of genetic information in countless FFPE collections that can now be unlocked with the combination of these technologies," Swift CEO Tim Harkins added in the statement.

Swift's deal with Silicon Biosystems follows a recent agreement to combine its Accel-Amplicon panels with Sophia Genetics' Data Driven Machine analytics platform.